Predictive factors for successful imatinib cessation in chronic myeloid leukemia patients treated with imatinib.

Predictive factors for successful imatinib cessation in chronic myeloid leukemia patients treated with imatinib.

Item
http://www.wikidata.org/entity/Q45897968
Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experienceImatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study.BCR-ABL1 transcripts (MR4.5) at post-transplant 3 months as an early predictor for long-term outcomes in chronic myeloid leukemia.Molecular monitoring to improve outcomes in patients with chronic myeloid leukemia in chronic phase: importance of achieving treatment-free remission.Transplant to treatment-free remission: the evolving view of 'cure' in chronic myeloid leukemia.Rationale and motivating factors for treatment-free remission in chronic myeloid leukemia.Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?Treatment-free remission in patients with chronic myeloid leukemia.Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.An Automated Homogeneous Immunoassay for Quantitating Imatinib Concentrations in Plasma.Baseline BCR-ABL1 transcript type of e13a2 and large spleen size are predictors of poor long-term outcomes in chronic phase chronic myeloid leukemia patients who failed to achieve an early molecular response after 3 months of imatinib therapy.Chronic Myeloid Leukemia-the Promise of Tyrosine Kinase Inhibitor Discontinuation.Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia.How I manage relapse of chronic myeloid leukaemia after stopping tyrosine kinase inhibitor therapy.Change of health-related profiles after Imatinib cessation in chronic phase chronic myeloid leukemia patients.Outcomes with frontline nilotinib treatment in Turkish patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.
P2860

Predictive factors for successful imatinib cessation in chronic myeloid leukemia patients treated with imatinib.

Item
http://www.wikidata.org/entity/Q45897968
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Predictive factors for success ...... atients treated with imatinib.
@en
Predictive factors for success ...... atients treated with imatinib.
@nl
type
label
Predictive factors for success ...... atients treated with imatinib.
@en
Predictive factors for success ...... atients treated with imatinib.
@nl
prefLabel
Predictive factors for success ...... atients treated with imatinib.
@en
Predictive factors for success ...... atients treated with imatinib.
@nl
P1433
P1476
P2093
P304
P31
P356
P433
P478
P50
P577
P698
P921
P356
P1433
P1476
Predictive factors for success ...... atients treated with imatinib.
@en
P2093
P304
P31
P356
P433
P478
P50
P577
P698
P921